Federal grants to Oncternal Therapeutics, Inc.
Oncternal Therapeutics, Inc. in San Diego, California received $3.9 million in federal grants from fiscal 2021 to 2025, across 3 awards. Its largest program was Extramural Research Programs in the Neurosciences and Neurological Disorders, with $2.1 million. In fiscal 2025 more was taken back from its awards than added, a net -$131,153.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$3.9 million
- Awards3
- Awarded in FY 2025-$131,153
- Largest award$1.8 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 2 | $1.2 million |
| FY 2022 | 1 | $1.0 million |
| FY 2023 | 1 | $753,745 |
| FY 2024 | 1 | $1.1 million |
| FY 2025 | 0 | -$131,153 |
Programs that fund Oncternal Therapeutics, Inc.
| Program | Awards | Amount |
|---|---|---|
| Extramural Research Programs in the Neurosciences and Neurological Disorders | 2 | $2.1 million |
| Cancer Treatment Research | 1 | $1.8 million |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 3 | $3.9 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| First-in-class ets inhibitor TK216: translational biology and oral dosage form development - TK216 is an investigational, potentially first-in-class, targeted small molecule that is designed to specifically inhibit the biological activity of the ets family of oncoproteins. Tumorigenic gene fusions i | Cancer Treatment Research | August 23, 2021 | $1.8 million |
| Preclinical development of ONCT-505, an androgen receptor antagonist and degrader, as new potential therapeutic for kennedy's disease - project summary kennedy’s disease, also known as spinobulbar muscular atrophy (SBMA), is a progressive neurodegenerative disease caused by genetic polyglutamine exp | Extramural Research Programs in the Neurosciences and Neurological Disorders | March 15, 2023 | $1.8 million |
| Selective androgen receptor degraders (SARDS) as new therapeutics for spinal and bulbar muscular atrophy (SBMA) - project summary kennedy’s disease also known as spinobulbar muscular atrophy (SBMA) is a progressive neurodegenerative disease caused by genetic polyglutamine expansion of the androgen r | Extramural Research Programs in the Neurosciences and Neurological Disorders | August 19, 2021 | $297,671 |
Questions people ask
How much federal grant money does Oncternal Therapeutics, Inc. get?
$3.9 million in 3 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Oncternal Therapeutics, Inc. the most?
The Department of Health and Human Services, with $3.9 million in 3 awards.
What is Oncternal Therapeutics, Inc.'s largest federal grant?
$1.8 million under Cancer Treatment Research, with its first action in the period on August 23, 2021. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Oncternal Therapeutics, Inc.?
Its largest are Extramural Research Programs in the Neurosciences and Neurological Disorders and Cancer Treatment Research.
Other grant recipients in San Diego
- San Diego Association of Governments
- Metropolitan Transit System
- General Atomics
- Neighborhood House Association
- San Diego County Regional Airport Authority
- San Diego State University Foundation
- San Diego Unified School District
- Family Health Centers of San Diego Inc
Largest federal grant recipients in California · Federal grants in California